These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
596 related articles for article (PubMed ID: 28427704)
1. Comparison of brain and spinal cord magnetic resonance imaging features in neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody. Fan M; Fu Y; Su L; Shen Y; Wood K; Yang L; Liu Y; Shi FD Mult Scler Relat Disord; 2017 Apr; 13():58-66. PubMed ID: 28427704 [TBL] [Abstract][Full Text] [Related]
2. Early and extensive spinal white matter involvement in neuromyelitis optica. Hayashida S; Masaki K; Yonekawa T; Suzuki SO; Hiwatashi A; Matsushita T; Watanabe M; Yamasaki R; Suenaga T; Iwaki T; Murai H; Kira JI Brain Pathol; 2017 May; 27(3):249-265. PubMed ID: 27082714 [TBL] [Abstract][Full Text] [Related]
3. Analysis of brain and spinal cord lesions to occult brain damage in seropositive and seronegative neuromyelitis optica. Sun J; Sun X; Zhang N; Wang Q; Cai H; Qi Y; Li T; Qin W; Yu C Eur J Radiol; 2017 Sep; 94():25-30. PubMed ID: 28941756 [TBL] [Abstract][Full Text] [Related]
4. Significance of gray matter brain lesions in multiple sclerosis and neuromyelitis optica. Kawachi I; Nishizawa M Neuropathology; 2015 Oct; 35(5):481-6. PubMed ID: 26079808 [TBL] [Abstract][Full Text] [Related]
5. Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis. Bensi C; Marrodan M; González A; Chertcoff A; Osa Sanz E; Chaves H; Schteinschnaider A; Correale J; Farez MF Mult Scler Relat Disord; 2018 Oct; 25():246-250. PubMed ID: 30144694 [TBL] [Abstract][Full Text] [Related]
6. Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis. Cortese R; Battaglini M; Prados F; Gentile G; Luchetti L; Bianchi A; Haider L; Jacob A; Palace J; Messina S; Paul F; Marignier R; Durand-Dubief F; de Medeiros Rimkus C; Apostolos Pereira SL; Sato DK; Filippi M; Rocca MA; Cacciaguerra L; Rovira À; Sastre-Garriga J; Arrambide G; Liu Y; Duan Y; Gasperini C; Tortorella C; Ruggieri S; Amato MP; Ulivelli M; Groppa S; Grothe M; Llufriu S; Sepulveda M; Lukas C; Bellenberg B; Schneider R; Sowa P; Celius EG; Pröbstel AK; Granziera C; Yaldizli Ö; Müller J; Stankoff B; Bodini B; Barkhof F; Ciccarelli O; De Stefano N; Ann Neurol; 2024 Aug; 96(2):276-288. PubMed ID: 38780377 [TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Matsuoka T; Matsushita T; Kawano Y; Osoegawa M; Ochi H; Ishizu T; Minohara M; Kikuchi H; Mihara F; Ohyagi Y; Kira J Brain; 2007 May; 130(Pt 5):1206-23. PubMed ID: 17439988 [TBL] [Abstract][Full Text] [Related]
8. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Misu T; Fujihara K; Kakita A; Konno H; Nakamura M; Watanabe S; Takahashi T; Nakashima I; Takahashi H; Itoyama Y Brain; 2007 May; 130(Pt 5):1224-34. PubMed ID: 17405762 [TBL] [Abstract][Full Text] [Related]
9. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068 [TBL] [Abstract][Full Text] [Related]
10. Quantitative brain lesion distribution may distinguish MOG-ab and AQP4-ab neuromyelitis optica spectrum disorders. Yang L; Li H; Xia W; Quan C; Zhou L; Geng D; Li Y Eur Radiol; 2020 Mar; 30(3):1470-1479. PubMed ID: 31748853 [TBL] [Abstract][Full Text] [Related]
11. Clinical manifestations of neuromyelitis optica in male and female patients. Yin J; Long Y; Shan F; Fan Y; Wu L; Zhong R; Gao C; Chen X; Gao Q; Yang N Neurol Res; 2015 Nov; 37(11):967-73. PubMed ID: 26213113 [TBL] [Abstract][Full Text] [Related]
12. [AQP4 immunohistochemistry in neuromyelitis optica and multiple sclerosis: a neuropathological review]. Yoshida M Brain Nerve; 2010 Sep; 62(9):961-74. PubMed ID: 20844307 [TBL] [Abstract][Full Text] [Related]
13. Differential patterns of spinal cord and brain atrophy in NMO and MS. Liu Y; Wang J; Daams M; Weiler F; Hahn HK; Duan Y; Huang J; Ren Z; Ye J; Dong H; Vrenken H; Wattjes MP; Shi FD; Li K; Barkhof F Neurology; 2015 Apr; 84(14):1465-72. PubMed ID: 25762714 [TBL] [Abstract][Full Text] [Related]
14. The prevalence of long spinal cord lesions and anti-aquaporin 4 antibodies in neuromyelitis optica patients in Taiwan. Wang KC; Tsai CP; Lee CL; Chen SY; Chen SJ Eur Neurol; 2011; 65(2):99-104. PubMed ID: 21273778 [TBL] [Abstract][Full Text] [Related]
15. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Takahashi T; Fujihara K; Nakashima I; Misu T; Miyazawa I; Nakamura M; Watanabe S; Shiga Y; Kanaoka C; Fujimori J; Sato S; Itoyama Y Brain; 2007 May; 130(Pt 5):1235-43. PubMed ID: 17449477 [TBL] [Abstract][Full Text] [Related]
16. Differentiate aquaporin-4 antibody negative neuromyelitis optica spectrum disorders from multiple sclerosis by multimodal advanced MRI techniques. Zhang N; Sun J; Wang Q; Qin W; Zhang X; Qi Y; Yang L; Shi FD; Yu C Mult Scler Relat Disord; 2020 Jun; 41():102035. PubMed ID: 32200338 [TBL] [Abstract][Full Text] [Related]
17. Anti-aquaporin-4 antibody positivity in neuromyelitis optica is associated with lesion activity. Liu Y; Han Y; Duan Y; Huang J; Ren Z; Butzkueven H; Li K Eur Neurol; 2013; 70(1-2):113-6. PubMed ID: 23860467 [TBL] [Abstract][Full Text] [Related]
18. Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity. Chien C; Scheel M; Schmitz-Hübsch T; Borisow N; Ruprecht K; Bellmann-Strobl J; Paul F; Brandt AU Mult Scler; 2019 Dec; 25(14):1926-1936. PubMed ID: 30475082 [TBL] [Abstract][Full Text] [Related]
19. Long-term MRI findings in neuromyelitis optica: seropositive versus seronegative patients. Kıyat-Atamer A; Ekizoğlu E; Tüzün E; Kürtüncü M; Shugaiv E; Akman-Demir G; Eraksoy M Eur J Neurol; 2013 May; 20(5):781-7. PubMed ID: 23279782 [TBL] [Abstract][Full Text] [Related]
20. Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD. Yan Y; Li Y; Fu Y; Yang L; Su L; Shi K; Li M; Liu Q; Borazanci A; Liu Y; He Y; Bennett JL; Vollmer TL; Shi FD Sci China Life Sci; 2016 Dec; 59(12):1270-1281. PubMed ID: 26920678 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]